Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03445858
Recruitment Status : Recruiting
First Posted : February 26, 2018
Last Update Posted : December 19, 2018
Sponsor:
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati

Brief Summary:

This pilot study is designed to assess the safety, tolerability, and preliminary anti-tumor activity of the combination of pembrolizumab, decitabine and fixed-dose hypofractionated index site radiotherapy in pediatric and young adult patients with relapsed, refractory or progressive non-primary CNS solid tumors and lymphomas.

Primary Objectives

  • To determine the feasibility of administering pembrolizumab in combination with decitabine and hypofractionated index lesion radiation
  • To identify the treatment-related toxicities and tolerability of the combination of decitabine and pembrolizumab
  • To identify the treatment related toxicity and tolerability of the combination of decitabine and pembrolizumab with hypofractionated index lesion radiation

Secondary Objective

To preliminarily define the anti-tumor efficacy of the combination of pembrolizumab, decitabine and hypofractionated index lesion radiation in patients with relapsed, refractory, or progressive non-CNS solid tumors and lymphomas using overall response rate (CR + PR) by irRECIST after 3 cycles (1 block) of therapy.

Exploratory Objectives

To profile the kinetics of the immune response and to correlate with promotor methylation changes, nuclear imaging, stool microbiota diversity, and tumor associated antigen immune responses.


Condition or disease Intervention/treatment Phase
Childhood Solid Tumor Childhood Lymphoma Relapsed Cancer Refractory Cancer Adult Solid Tumor Adult Lymphoma Drug: Pembrolizumab Drug: Decitabine Radiation: Hypofractionated Index Site Radiation Early Phase 1

Detailed Description:

Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course of fixed-dose hypofractionated index site radiotherapy to one or more index lesions.

One cycle lasts 28 days. One block lasts 84 days (3 cycles per block). Radiation is given in block 1 only (cycle 2 only). Blocks may repeat for a total of 9 times (27 cycles) if patient meets criteria to continue protocol therapy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatric and Young Adult Patients With Relapsed and Refractory Solid Tumors or Lymphoma
Actual Study Start Date : February 12, 2018
Estimated Primary Completion Date : May 12, 2022
Estimated Study Completion Date : May 12, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Pembrolizumab, Decitabine, Radiation
Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions.
Drug: Pembrolizumab
Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. One block lasts 84 days (3 cycles per block). Blocks may repeat for a total of 9 times (27 cycles) if patient meets criteria to continue protocol therapy.
Other Name: Keytruda

Drug: Decitabine
Patients will receive decitabine every 28 days.One cycle lasts 28 days. One block lasts 84 days (3 cycles per block). Blocks may repeat for a total of 9 times (27 cycles) if patient meets criteria to continue protocol therapy.
Other Name: Dacogen

Radiation: Hypofractionated Index Site Radiation
Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during Block 1 only.




Primary Outcome Measures :
  1. Feasibility of administering Pembrolizumab in combination with Decitabine and hypofractionated index radiation [ Time Frame: Days 1 thru 57 ]
    Incidence of number of patients who experience a DLT


Secondary Outcome Measures :
  1. Identification of treatment related toxicities and tolerability [ Time Frame: Days 1 thru 57 ]
    Incidence of adverse events (toxicities) according to NCI CTCAE version 4.0

  2. Define anti-tumor efficacy of treatment combination of pembrolizumab, decitabine, and hypofractionated index radiation (per irRECIST criteria) [ Time Frame: 3 cycles (84 days) ]
    Incidence of patients who experience an overall complete response or partial response to study treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Months to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Criteria: Inclusion Criteria:

  • Age: greater than or equal to 12 months and less than or equal to 40 years.
  • Diagnosis: Patients must have had histologic verification of malignancy at original diagnosis or relapse. Eligible diagnoses include:

    • Relapsed or refractory solid tumors (excluding primary CNS tumors)
    • Lymphoma in second or greater relapse or with refractory disease
  • Disease Evaluation: Patients must have evaluable or measurable disease (patients with evaluable disease must have at least one lesion that is amenable to radiation as below).
  • Patients with stable non-brainstem CNS metastases may be eligible.
  • Therapeutic Options: Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.
  • Performance Level: Lansky/Karnofsky greater than or equal to 50.
  • Prior Therapy: Patients who have previously received inhibitors of PD-1, PD-L1, CTLA4 or other immune checkpoint inhibitors, regardless of response, are eligible as long as they had not experienced a medically significant immune related adverse event that required treatment with supraphysiologic steroids or other immunomodulatory drug.
  • Patients must have recovered from the acute toxic effects of all prior anti-cancer chemotherapy and meet the following:

    • Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).
    • Hematopoietic growth factors: At least 21 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor.
    • Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent.
    • Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.
    • Monoclonal antibodies: At least 4 weeks after the last dose of a monoclonal antibody.
    • XRT: At least 14 days after local palliative XRT (limited field); At least 150 days must have elapsed if prior TBI, craniospinal XRT or radiation treatment resulting in greater than or equal to 50% of the pelvis receiving greater than or equal to 10 Gy.
    • Stem Cell Infusion without TBI: At least 84 days must have elapsed after autologous stem cell transplant or stem cell infusion. Patients having received allogeneic stem cells within the past 5 years are not eligible.
  • Adequate Bone Marrow Function Defined as:

    • Peripheral absolute neutrophil count (ANC) greater than or equal to 750/mm3
    • Platelet count greater than or equal to 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
    • Hemoglobin greater than or equal to 8 (transfusions allowed)
    • Patients with known bone marrow involvement will be eligible for the study provided that they have a platelet count of greater than or equal to 50,000/mm3 (transfusion independent, defined as not receiving platelet transfusion for at least 7 days prior to enrollment).
  • Adequate Renal Function Defined as:

    o Creatinine clearance, cystatin C based GFR, or radioisotope GFR greater than or equal to 70ml/min/1.73 m2 or a serum creatinine based on protocol requirements.

  • Adequate Liver Function Defined as:

    • Direct bilirubin less than or equal to 1.5 x upper limit of normal (ULN) for age
    • SGPT (ALT) less than or equal to 3.0 x upper limit of normal (ULN). For patients with known liver metastases or primary tumor, SGPT (ALT) less than or equal to 5 x upper limit of normal (ULN) may be accepted. For the purposes of this study, the ULN of SGPT is 45 U/L.
  • Adequate Cardiac Function Defined as:

    • Ejection fraction of greater than or equal to 50% by echocardiogram (3D if available) or cardiac MRI.
    • QTC less than or equal to 480 msec.
  • Adequate Pulmonary Function Defined as:

    o Pulse oximetry greater than 94% on room air and no dyspnea at rest.

  • Radiation Considerations:

    • Patients must have at least one non-CNS lesion amenable to radiation as defined in the protocol and at the discretion of the Study Chair.
    • Patients with previously irradiated sites of disease may be considered eligible if potential index lesions meet the following: There has been documented progression at that site (by RECIST or for neuroblastoma patients enrolled with evaluable disease, persistent MIBG avidity), and Re-irradiation would not expose the patient to a substantial increase in toxicity (as determined by consultation with co-principal investigator or designee and treating oncologist).

Exclusion Criteria:

  • Patients with primary CNS tumors, brainstem metastases, and/or carcinomatous meningitis are not eligible.
  • Pregnant or breast-feeding women will not be entered on this study.
  • Corticosteroids and other immunosuppressive therapy: Patients requiring systemic corticosteroids or other immunosuppressive medication within 7 days prior to enrollment are not eligible with the exception of physiologic replacement doses of corticosteroids.
  • Patients who are currently receiving another investigational drug are not eligible.
  • Patients who are currently receiving other anti-cancer agents are not eligible.
  • Patients with a history of an autoimmune disorder are not eligible. Asymptomatic laboratory abnormalities (e.g. ANA, rheumatoid factor) will not render a patient ineligible in the absence of a diagnosis of an autoimmune disorder.
  • Patients with known hepatitis B (HBsAg reactive) or C (HCV RNA -qualitative is detected) are excluded.
  • Patients with HIV are excluded if they have detectable viral loads or CD4 count is below 400 or they are not compliant with antiretroviral agents.
  • Patients who have an uncontrolled infection are not eligible.
  • Patients with immunodeficiency syndromes are not eligible.
  • Patients with a history of clinically significant cardiac disease are not eligible.
  • Patients with ongoing interstitial lung disease or pneumonitis are not eligible.
  • Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).
  • Patients who have received a live vaccine less than or equal to 30 days prior to enrollment are ineligible.
  • Patients who have received a prior solid organ transplant at any time, or allogeneic bone marrow transplantation within the past 5 years (or have signs or symptoms of GVHD) are not eligible.

Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03445858


Contacts
Layout table for location contacts
Contact: Laura Fossett (513) 636-2799 cancer@cchmc.org
Contact: Brian Turpin, DO Brian.Turpin@cchmc.org

Locations
Layout table for location information
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Laura Fossett    513-636-2799    cancer@cchmc.org   
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Investigators
Layout table for investigator information
Principal Investigator: Brian Turpin, DO Children's Hospital Medical Center, Cincinnati

Layout table for additonal information
Responsible Party: Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier: NCT03445858     History of Changes
Other Study ID Numbers: Pembro_BT_1603
First Posted: February 26, 2018    Key Record Dates
Last Update Posted: December 19, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pembrolizumab
Lymphoma
Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Decitabine
Antineoplastic Agents, Immunological
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors